PharmAbcine

54 articles about PharmAbcine

• PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex

  6/26/2020

  PharmAbcine (KRX: 208340) (GM: Jin-san Yoo), biotech company focusing on the development of antibody therapeutics, announced on 18th that it had signed a contract manufacturing organization(CMO) agreement with biologics contract development and manufacturing organization (CDMO) Binex for additional production of investigationa

• PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I

  6/10/2020

  PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer.

• PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas

  6/3/2020

  PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value of PharmAbcine's existing and future assets through R&D efforts. U

• PharmAbcine to Participate in BIO Digital Conference

  5/27/2020

  The BIO International Convention is holding its annual event virtually this year amidst the COVID-19 global pandemic. The event brings together capital, scientific and development expertise needed to turn promising innovation into successful medicine.

• PharmAbcine to Present Preclinical Data of Blood Vessel Stabilizing PMC-402 at 2020 AACR Meeting

  5/19/2020

  PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present preclinical data of PMC-402, an active vessel stabilizing monoclonal antibody, at the 2020 American Association for Cancer Research (AACR).

• Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

  4/6/2020

  Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders.

• PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting

  4/3/2020

  PharmAbcine Inc. (KOSDAQ: 208340) announced today that the abstract summarizing interim data on its phase Ib trial of olinvacimab in combination with Merck’s anti-PD-1 antibody Keytruda® for recurrent glioblastoma multiforme (rGBM) patients has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

• PharmAbcine to Participate in Both J.P. Morgan Health Conference 2020 and Biotech Showcase in San Francisco, Ca, USA

  1/8/2020

  During the week of conference, PharmAbcine will evaluate and discuss strategic partnership with a number of global pharmaceutical companies, global investment bankers, biopharma and innovative biotech companies.

• PharmAbcine’s Olinvacimb, able to manage the first recruitment of patients for phase II clinical trial

  11/25/2019

  Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia

• PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma

  10/2/2018

  PharmAbcine, Inc. announces that the company received “Study May Proceed Letter “ from the US Food and Drug Administration (FDA) for the Investigational New Drug (“IND”) application of its flagship antibody, TTAC-0001.

• PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme

  4/1/2018

  PharmAbcine Inc. announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its leading clinical compound TTAC-0001 for “treatment of Glioblastoma Multiforme.”

• PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA® (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer

  2/1/2018

  PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications.

• PharmAbcine Announces Global Licensing Deal With Triphase Accelerator For VEGFR-2/TIE 2 Bi-Specific Antibody

  10/28/2014

• PharmAbcine Closes USD $6 Million Series A Financing

  9/17/2009